An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.
Q X Zhang, A Borg, D M Wolf...
https://pubmed.ncbi.nlm.nih.gov/9102207/Actively Recruiting
Led by Hellenic Cooperative Oncology Group · Updated on 2026-10-27
500
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are studying the presence of ESR1 gene mutations in patients with metastatic hormone receptor-positive and HER2-negative breast cancer in Greece. This observational study aims to understand how these mutations relate to disease features, treatment history, and patient outcomes, using data from routine clinical care. The study includes both retrospective and prospective data collection and is supported by the Hellenic Cooperative Oncology Group. Participants in this study have already undergone ESR1 mutation testing as part of their usual care. No changes to their treatment are required. Data collection involves extracting information from medical records during routine visits, including mutation status, clinical features, and treatment patterns. Patients may also optionally provide biological samples for further molecular analysis. During the study, researchers will gather data from standard clinical visits without additional procedures or extra visits. Personal data are carefully protected through coding and pseudonymization. The main measurement is the prevalence of ESR1 mutations, with additional analysis on how these mutations associate with prior therapies and other biomarkers. The study follows all relevant privacy and safety regulations and is expected to continue for about one year on average.
CONDITIONS
ESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population
E
Eleni Galani
M
Maria Moschoni
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hellenic Cooperative Oncology Group
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Approximately 1 year
Clinical and treatment data are collected from participants' medical records during routine clinical visits. No additional procedures or visits are required.
Routine clinical visits as scheduled by the participant's physician
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Q X Zhang, A Borg, D M Wolf...
https://pubmed.ncbi.nlm.nih.gov/9102207/Gayathri Nagaraj, Cynthia X Ma
https://pubmed.ncbi.nlm.nih.gov/33190190/Dan R Robinson, Yi-Mi Wu, Pankaj Vats...
https://pubmed.ncbi.nlm.nih.gov/24185510/Weiyi Toy, Yang Shen, Helen Won...
https://pubmed.ncbi.nlm.nih.gov/24185512/Keren Merenbakh-Lamin, Noa Ben-Baruch, Adva Yeheskel...
https://pubmed.ncbi.nlm.nih.gov/24217577/Francisco Hermida-Prado, Rinath Jeselsohn
https://pubmed.ncbi.nlm.nih.gov/33526469/Rinath Jeselsohn, Roman Yelensky, Gilles Buchwalter...
https://pubmed.ncbi.nlm.nih.gov/24398047/Shunqiang Li, Dong Shen, Jieya Shao...
https://pubmed.ncbi.nlm.nih.gov/24055055/Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven...
https://pubmed.ncbi.nlm.nih.gov/35584336/Hellenic Cooperative Oncology Group
Lead Sponsor